Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026

Larimar Therapeutics, Inc.

2025-Q2 EPS reported -$0.87 vs consensus -$0.49 ▼ miss (-77.6%)

Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.
Cash, equivalents, marketable securities $138.5M at June 30; pro forma $203.6M incl. $65.1M July offering; runway into Q4 2026.
FDA recommends safety database: 30+ participants on 50 mg for 6 months, subset of 10 for 1 year.
Initial 50 mg open-label and adolescent PK run-in data expected September 2025.
Global Phase 3 sites identified in US, EU, UK, Canada, Australia; patient recruitment to begin later 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.